Effects of different OADs on intensive therapy of continuous subcutaneous insulin infusion treatment for type 2 diabetes

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025034

Enrollment

Unknown

Registered

2019-08-08

Start date

2018-10-09

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly diagnosed type 2 diabetes mellitus

Interventions

Group 1:Insulin+Metformin 1000mg bid

Group 2:Insulin+Dapagliflozin 10mg qd

Group 3:Insulin Lispro

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed type 2 diabetes with marked hyperglycemia (glycosylated hemoglobin > 9%, or fasting blood glucose higher than 11.1mmol/L); 2. BMI 18.5 Kg/m2 to 40Kg/m2, and aged 30 to 65 years old.

Exclusion criteria

Exclusion criteria: 1. combined with serious infections; 2. with acute complications (such as hyperglycemia and hyperosmotic state, diabetic ketoacidosis, etc.); 3. with trauma, severe malnutrition, severe liver and kidney dysfunction (transaminase 3 times higher than normal value, eGFR higher than 60%); 4. type 1 diabetes; 5. pregnant or lactating women and women with pregnancy requirements.

Design outcomes

Primary

Measure	Time frame
fasting blood-glucose;FINS;HbA1c;C-peptide;	—

Countries

China

Contacts

Public ContactYing Zhang

The Third Affiliated Hospital of Guangzhou Medical University

zhangying30412@163.com+86 18928916685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026